Malignant hypercalcemia and thrombocytopenia may result from bone metastasis of cholangiocarcinoma (CC). Our case was 53-year-old man admitted to emergency department with symptoms of anorexia, weight loss, nausea, vomiting, and general fatigue in February 2012. His laboratory findings showed hypercalcemia and thrombocytopenia. CT showed a large multinodular mass in the right lobe and, extending through left lobe of the liver. We considered the diagnosis of hypercalcemia of malignancy with elevated calcium levels and suppressed PTH level with the existence of skeletal bone metastasis and the absence of parathyroid gland pathology. Treatment of hypercalcemia with IV saline, furosemide, and calcitonin improved the patient symptoms. After the ...
Hypercalcemia is a common electrolyte imbalance in patients with malignancy. Approximately 80% of hy...
Background: Hypercalcemia is a common paraneoplastic syndrome which can occur in up to 10% of patien...
Hypercalcemia of malignancy (HM) is the most common metabolic disorder in cancer patients, represent...
Humoral hypercalcemia of malignancy (HHM) is rarely associated with cholangiocarcinoma (CC), and rep...
Humoral hypercalcemia of malignancy (HHM) is most commonly encountered in squamous cell carcinoma (S...
Different mechanisms are responsible for hypercalcemia, enclosed: (1) degradation of bone matrix in ...
Background - Hypercalcemia of malignancy is relatively common in several cancers. However, in colore...
Hypercalcemia of malignancy frequently manifests as paraneoplastic syndrome in patients with solid t...
Abstract One of the most common metabolic abnormalities found in patients with malignancy is hyperca...
Key Clinical Message A 76‐year‐old patient previously admitted to the cardiology department for repl...
Hypercalcemia is a common paraneoplastic syndrome that may result in metastatic calcification. We re...
Malignancy is one of the most common causes of hypercalcemia, particularly in cancer associated with...
Hypercalcemia caused by parathyroid carcinoma is an extremely rare malignancy, with resulting higher...
Hypercalcemia is a common complication of malignancy and portends a worse prognosis. It causes a var...
Hepatocellular carcinoma (HCC) is the fifth most common cancer in Korea. Diverse paraneoplastic synd...
Hypercalcemia is a common electrolyte imbalance in patients with malignancy. Approximately 80% of hy...
Background: Hypercalcemia is a common paraneoplastic syndrome which can occur in up to 10% of patien...
Hypercalcemia of malignancy (HM) is the most common metabolic disorder in cancer patients, represent...
Humoral hypercalcemia of malignancy (HHM) is rarely associated with cholangiocarcinoma (CC), and rep...
Humoral hypercalcemia of malignancy (HHM) is most commonly encountered in squamous cell carcinoma (S...
Different mechanisms are responsible for hypercalcemia, enclosed: (1) degradation of bone matrix in ...
Background - Hypercalcemia of malignancy is relatively common in several cancers. However, in colore...
Hypercalcemia of malignancy frequently manifests as paraneoplastic syndrome in patients with solid t...
Abstract One of the most common metabolic abnormalities found in patients with malignancy is hyperca...
Key Clinical Message A 76‐year‐old patient previously admitted to the cardiology department for repl...
Hypercalcemia is a common paraneoplastic syndrome that may result in metastatic calcification. We re...
Malignancy is one of the most common causes of hypercalcemia, particularly in cancer associated with...
Hypercalcemia caused by parathyroid carcinoma is an extremely rare malignancy, with resulting higher...
Hypercalcemia is a common complication of malignancy and portends a worse prognosis. It causes a var...
Hepatocellular carcinoma (HCC) is the fifth most common cancer in Korea. Diverse paraneoplastic synd...
Hypercalcemia is a common electrolyte imbalance in patients with malignancy. Approximately 80% of hy...
Background: Hypercalcemia is a common paraneoplastic syndrome which can occur in up to 10% of patien...
Hypercalcemia of malignancy (HM) is the most common metabolic disorder in cancer patients, represent...